From Infusion to Injection: Can Subcutaneous Delivery Match Intravenous Standards in Oncology?
Optimizing Immunotherapy for Advanced NSCLC: How to Manage Immune Toxicities
Jacob Sands, MD
Christine Bestvina, MD
Optimizing Second-Line CAR T Decisions in R/R Large B-Cell Lymphoma
Charles Turck, PharmD, BCPS, BCCCP
Sairah Ahmed, MD
Enhancing Efficacy and Safety in HR+/HER2- Breast Cancer with Novel PI3Kα Inhibitors
Neil M. Iyengar, MD
Advancing Endometrial Cancer Care: ADCs and Biomarker-Based Therapies
Brian Slomovitz, MD
Redefining First-Line Treatment in Endometrial Cancer: The Role of Immunotherapy
From Infusion Chair to Clinic Visit: How Subcutaneous Nivolumab May Simplify RCC Care
Novel Therapies in Extensive-Stage Small Cell Lung Cancer (ES-SCLC)
Stephen Liu, MD
Joshua K. Sabari, MD
Susan Scott, MD
Clinical Implications of Neoadjuvant Therapy Guideline Updates in Resectable Melanoma
John M. Kirkwood, MD
Sapna Patel, MD
Reimagining Lung Cancer Treatment: A Journey Through New and Emerging Therapeutics Related to the Care of Patients with Small Cell and Non-Small Cell Lung Cancer
Innovations in Oncology Learning Center: From Guidelines to Practice: Melanoma
Paolo A. Ascierto, MD
Hussein Tawbi, MD, PhD
MET and Other Emerging Targets in Metastatic NSCLC
HER2-Driven Strategies in Metastatic NSCLC
Strategies in EGFR-mutated Unresectable Stage III NSCLC
Insights From Global Key Opinion Leaders on Regional Regulatory and Guideline Nuances to Optimize Melanoma Management
Data Driving Preferred Guideline Recommendations in First-Line Therapy for Metastatic Melanoma
Loading...
NEW FEATURES:
Tell us what you think by using the Feedback button on the right side of the page.
We're glad to see you're enjoying Global Oncology Academy… but how about a more personalized experience?
Press cancel to remain on Global Oncology Academy. Press the link below or the continue button to keep going.